1. |
- Cornelissen, Gerard, et al.
(författare)
-
Transport of polycyclic aromatic hydrocarbons and polychlorinated biphenyls in a landfill : A novel equilibrium passive sampler to determine free and total dissolved concentrations in leachate water
- 2009
-
Ingår i: Journal of Hydrology. - : Elsevier BV. - 0022-1694 .- 1879-2707. ; 369:04-mar, s. 253-259
-
Tidskriftsartikel (refereegranskat)abstract
- Equilibrium passive sampling devices consisting of 17-mu m thick polyoxymethylene (POM) were in situ deployed as a novel technique for landfill groundwater leachate water sampling of freely dissolved poly-cyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs). POM was deployed in two groundwater leachate wells (flow around 100 m y(-1)) and an effluent leachate tank. The dissipation of >90% of spiked performance reference compounds and comparison between 60 d and 140 d of equilibration confirmed that POM-water equilibrium was reached for all PAHs and most PCBs within 60 d. Comparison of total and freely dissolved concentrations yielded dissolved organic carbon-water distribution ratios that were on average 0.4 log-unit below amorphous organic carbon-water distribution ratios and in accordance with literature values. Particle-bound fractions ranged from 50% (small PAHs) to 99.9% (large PCBs), and were >95% for most compounds. It was concluded that POM-17 equilibrium passive samplers provide a facile method to measure freely dissolved concentrations of PAH and PCB in groundwater leachate, which will yield valuable information on its ecotoxicological risk for aquatic and benthic organisms.
|
|
2. |
- Druker, Brian J., et al.
(författare)
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
- 2006
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 355:23, s. 2408-2417
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
|
|
3. |
|
|
4. |
- Stevens, Jan, 1955, et al.
(författare)
-
Wiskundig onderzoek per computer?
- 2009
-
Ingår i: Nieuw Archief voor Wiskunde. - 0028-9825. ; (5) 10:3, s. 197-200
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|